Phase 2 Data: Celldex Therapeutics’ Barzolvolimab Performs Well in CSU, CIndU
Celldex Therapeutics’ barzolvolimab demonstrated improved disease control and quality of life in Phase 2 studies of patients with chronic spontaneous urticaria and chronic inducible urticaria (CIndU). Barzolvolimab is a humanized monoclonal antibody that specifically binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity, which is required for mast cell function […]